ARHGEF5

ARHGEF5 Full Name

Rho guanine nucleotide exchange factor (GEF) 5

ARHGEF5 Introduction

ARHGEF5 (Rho guanine nucleotide exchange factor 5, also known as p60 or TIM) is a member of the Dbl family of RhoGEFs that activate Rho family small GTPases by catalyzing the exchange of GDP for GTP. The gene is located on chromosome 7q34 and encodes a protein of 593 amino acids with a molecular weight of approximately 60 kDa (p60). ARHGEF5 is expressed in a wide range of human tissues, including the brain, heart, placenta, lung, liver, kidney, pancreas, and various cancer cell lines. The protein functions as a guanine nucleotide exchange factor (GEF) with specificity for RhoA, Rac1, and to a lesser extent, Cdc42, positioning it as a regulator of both actin cytoskeleton dynamics and cell signaling. ARHGEF5 is particularly notable for its overexpression in several human cancers, where it promotes tumor progression, invasion, metastasis, and chemoresistance. The protein localizes to the cytoplasm and can translocate to the plasma membrane upon activation, where it facilitates the activation of Rho GTPases. In addition to its role in cancer, ARHGEF5 has been implicated in T-cell activation, neurite outgrowth, and cellular responses to oxidative stress, reflecting its diverse roles in normal physiology and disease.

Figure 1. Schematic structure of ARHGEF5.

Structural Characteristics and Molecular Binding Mechanism of ARHGEF5
ARHGEF5 possesses a canonical conserved Dbl-family multi-domain architecture that defines its substrate specificity, catalytic activity, and subcellular localization. The core functional module consists of tandem Dbl homology (DH) and pleckstrin homology (PH) domains, which are essential for its guanine nucleotide exchange activity. The DH domain mediates direct physical interaction with Rho family GTPases, specifically promoting GDP dissociation and GTP loading for RhoA and RhoB, while displaying weak activity toward RHOC and negligible affinity for Rac1 and other Rho subfamily members. The PH domain binds selectively to membrane phosphoinositides, anchoring ARHGEF5 to the plasma membrane and cytoskeletal compartments to optimize catalytic efficiency and spatial signal transduction. ARHGEF5 also contains unique auxiliary protein-binding motifs that enable specific interaction with cytoskeletal regulatory proteins such as Drebrin, linking GEF activity to microtubule acetylation and cytoskeletal stability. Under basal conditions, ARHGEF5 maintains a resting conformational state to prevent aberrant Rho signaling activation, while extracellular stimuli trigger conformational activation to initiate downstream signaling. Structural mutations or domain dysfunction disrupt GTPase activation ability, leading to impaired cytoskeletal dynamics and abnormal cellular migration phenotypes.

Cancer Progression and Chemoresistance
ARHGEF5 is frequently overexpressed in multiple human cancers, and its overexpression correlates with tumor progression, metastasis, and poor patient survival. In breast cancer, ARHGEF5 is significantly upregulated in tumor tissues compared to adjacent normal tissues, particularly in aggressive subtypes including triple-negative breast cancer (TNBC). High ARHGEF5 expression correlates with advanced tumor grade, lymph node metastasis, and reduced overall survival. ARHGEF5 promotes breast cancer cell migration, invasion, and metastasis by activating Rac1 and RhoA, leading to increased invadopodia formation, extracellular matrix degradation, and epithelial-mesenchymal transition (EMT). Knockdown of ARHGEF5 in breast cancer cell lines suppresses tumor growth and metastasis in mouse xenograft models, and enhances sensitivity to chemotherapy. In colorectal cancer (CRC), ARHGEF5 is overexpressed and promotes cancer cell proliferation, migration, and invasion. High ARHGEF5 expression correlates with poor differentiation, advanced TNM stage, and shorter disease-free survival. ARHGEF5 promotes CRC progression by activating the Wnt/β-catenin signaling pathway and by upregulating the expression of matrix metalloproteinases (MMP2, MMP9). In lung cancer (non-small cell lung cancer, NSCLC), ARHGEF5 is overexpressed and promotes cell proliferation, migration, and resistance to cisplatin and other chemotherapeutic agents. ARHGEF5 also protects cancer cells from apoptosis by activating the PI3K/AKT survival pathway and by upregulating anti-apoptotic proteins including BCL2 and BCL-XL. In pancreatic cancer, gastric cancer, hepatocellular carcinoma (HCC), and glioblastoma, ARHGEF5 overexpression has also been reported, with consistent associations with aggressive tumor behavior and poor prognosis. The mechanisms by which ARHGEF5 is upregulated in cancer include gene amplification (the 7q34 region is frequently amplified in some cancers), transcriptional activation by oncogenic transcription factors (including E2F1, MYC, and HIF-1α), and post-transcriptional regulation by microRNAs (including miR-34a, miR-200b, and miR-145, which are frequently downregulated in cancer).

Alternate Names for ARHGEF5

ARHGEF5; Rho guanine nucleotide exchange factor (GEF) 5;